VISHEE(SH:688580) Sou Hu Cai Jing·2025-10-23 22:10Core Insights - Weisi Medical (688580) reported a strong performance in its Q3 2025 financial results, with both revenue and net profit showing significant year-on-year growth [1] - The company achieved a total revenue of 326 million yuan, an increase of 11.58% compared to the previous year, and a net profit of 102 million yuan, up 30.68% year-on-year [1] Financial Performance - Q3 2025 total revenue reached 115 million yuan, reflecting a 14.87% increase year-on-year [1] - Q3 2025 net profit was 32.82 million yuan, marking a 14.99% rise compared to the same quarter last year [1] - Gross margin improved to 66.86%, up 0.93% year-on-year, while net margin increased to 31.38%, a rise of 17.12% [1] - Total operating expenses (selling, administrative, and financial) amounted to 91.41 million yuan, accounting for 28.08% of revenue, down 8.42% year-on-year [1] Key Ratios and Metrics - Earnings per share (EPS) for Q3 2025 was 1.07 yuan, a 30.49% increase from the previous year [1] - The company reported a significant increase in operating cash flow per share to 1.09 yuan, up 69.02% year-on-year [1] - The company's return on invested capital (ROIC) was 5.69% last year, with a historical median ROIC of 23.96% since its listing [5] Market Position and Fund Holdings - The largest fund holding Weisi Medical shares is Beixin Ruifeng Health Life, which reduced its holdings to 75,000 shares as of Q3 2025 [4] - The fund's current size is 0.9 billion yuan, with a recent net value of 1.227, reflecting a 0.65% decline from the previous trading day [6]